Skip to main content
Premium Trial:

Request an Annual Quote

Novozymes, ProMetic in Protein Purification Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Novozymes and ProMetic Life Sciences today announced a co-marketing alliance for an albumin purification technology based on a synthetic-ligand affinity adsorbent developed by ProMetic's UK subsidiary, ProMetic BioSciences.

The purification technology was designed for the rapid and cost-effective development of Novozymes' albufuse albumin-fusion molecules, the firms said.

Under terms of the alliance, the firms will jointly promote the use of the new adsorbent, marketed under the trade-name AlbuPure, as a platform approach for the purification of albumin and albumin-fusion proteins. ProMetic will serve as exclusive manufacturer and supplier of AlbuPure, but both parties will retain ownership of their respective technologies and both Novozymes and ProMetic will have the right to market AlbuPure.

"This alliance with ProMetic will enable us to expand the technology package offered to our clients to include both protein expression and protein purification technology for albumin-fusion proteins," Dave Mead, business development director of Novozymes Biopharma, said in a statement. "The availability of a robust affinity capture step, fully supported by Novozymes Biopharma and ProMetic, will provide significant advantages to our clients, including reduced development times and simplified high-yield manufacturing processes."

Further terms of the alliance were not disclosed.

The Scan

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.